CorMedix Boosts Revenue and Raises EBITDA Guidance on Strong DefenCath Sales
Event summary
- CorMedix reported Q2 2026 revenue of $101.9 million, up from $39.7 million in Q2 2025.
- DefenCath sales contributed $66.1 million, driven by large outpatient dialysis customers.
- Adjusted EBITDA rose to $58.7 million, prompting the company to raise full-year guidance to $125–$140 million.
- CorMedix anticipates FDA submission for REZZAYO’s expanded indication in Q3 2026.
- The company signed a multi-year commercial supply agreement with a top 5 U.S. dialysis provider.
The big picture
CorMedix’s strong Q2 performance reflects sustained demand for DefenCath in dialysis care, while its raised EBITDA guidance signals confidence in cost discipline. The pending REZZAYO submission could expand its infectious disease portfolio, but execution hinges on FDA approval timelines and commercial adoption rates.
What we're watching
- Regulatory Timing
- Whether the FDA will accept and act on REZZAYO’s sNDA submission in H1 2027.
- Commercial Execution
- How CorMedix integrates the new dialysis operator contract into its revenue pipeline.
- Cost Management
- The pace at which operating expenses rise as the company scales post-Melinta acquisition.